Please assess the completion status of the following clinical trial:

Trial Title: Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria for Subjects 9 - 40 Years of Age:~* Healthy~* Properly informed about the study and having signed the informed consent form~* Subject/Parent will commit themselves to comply with the instructions of the investigator and the schedule of the trial.~Inclusion Criteria for Subjects 6 Months - 8 Years of Age:~* Healthy~* Parents have been informed properly regarding the study and signed the informed consent form~* Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial~Exclusion Criteria:~* Subject concomitantly enrolled or scheduled to be enrolled in another trial~* Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature \>= 37.5 C )~* Known history of allergy to egg and or chicken protein or any component of the vaccines~* History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection~* Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (\> 2 weeks).~* Pregnancy \& Lactation (Adult)~* Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives~* Subject already immunized with influenza vaccine within 1 year.~* Subjects receive any vaccination within 1 month before and after immunization of Quadrivalent Influenza Vaccine.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- QIV batch 1 (Type: EXPERIMENTAL): 1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
- QIV batch 2 (Type: EXPERIMENTAL): 1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
- QIV batch 3 (Type: EXPERIMENTAL): 1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
- Trivalent Influenza Vaccine (Type: ACTIVE_COMPARATOR): 1 dose of 0.5 ml of trivalent influenza vaccine
- QIV (subjects 6-35 months) (Type: EXPERIMENTAL): 2 dose of 0.25 ml of quadrivalent influenza vaccine
- QIV (subjects 3-8 years) (Type: EXPERIMENTAL): 2 dose of 0.5 ml of quadrivalent influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).